Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 12/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21554260 | 0.90 | MKNK1 (0.38) | CYP2D6IDO1 | |
| SCHEMBL22304478 | 0.90 | MKNK1 (0.38) | CYP2D6IDO1 | |
| SCHEMBL3312248 | 0.81 | HDAC1 (0.44) | CYP2D6CXCR4IDO1HDAC1HDAC6 | |
| SCHEMBL10286472 | 0.81 | HDAC1 (0.44) | CYP2D6CXCR4IDO1HDAC1HDAC6 | |
| SCHEMBL9934087 | 0.80 | HDAC1 (0.38) | CYP2D6CXCR4IDO1HDAC1HDAC6 | |
| SCHEMBL2147997 | 0.79 | CYP2D6 (0.37) | CYP2D6CXCR4IDO1HDAC1HDAC6 | |
| SCHEMBL20465818 | 0.79 | SLC18A3 (0.33) | CYP2D6 | |
| SCHEMBL12891529 | 0.77 | CYP2D6 (0.43) | CYP2D6CXCR4HDAC1HDAC6 | |
| SCHEMBL2083952 | 0.77 | CXCR4 (0.43) | CYP2D6CXCR4HDAC1HDAC6 | |
| SCHEMBL2084964 | 0.77 | CXCR4 (0.43) | CYP2D6CXCR4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108963-B2 | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108963-B2 | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-08-18 | — | — | US | disclosed |
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | CYP2D6 2649/4885CXCR4 1793/4885IDO1 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.